PPIDT00104
Drug Information
| Name | Ranibizumab |
|---|---|
| Sequence | DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB01270 |
| Type | biotech |
| Indication | Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization by the FDA.[L38978, L41434] Ranibizumab injection for intravitreal use via ocular implant is used to treat Neovascular (wet) Age-related Macular Degeneration (AMD) in patients who have responded to at least two intravitreal injections of a VEGF inhibitor.[L38983] In Canada, ranibizumab is approved to treat adult patients with neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema, macular edema secondary to retinal vein occlusion, choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), and choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, postinflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy.[L49136] In Europe, ranibizumab is also approved for the treatment of similar ophthalmological conditions, including neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), and visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) or choroidal neovascularisation (CNV) for adults and retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease for preterm infants.[L41434] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravitreal |
10 MG/ML
|
| Injection, solution | Intravitreal |
0.3 mg/0.05mL
|
| Injection, solution | Intravitreal |
0.5 mg/0.05mL
|
| Injection, solution | Intravitreal |
10 mg/1mL
|
| Injection, solution | Intravitreal |
6 mg/1mL
|
| Solution | Intraocular |
2.300 mg
|
| Solution | Intravitreal |
10 mg / mL
|
| Injection, solution | Ophthalmic |
10 mg/ml
|
| Injection, solution | Intraocular |
10 MG/ML
|
| Injection, solution | Intraocular |
2.3 mg
|
| Injection, solution | Intraocular |
1.65 mg/0.165ml
|
| Solution | Ophthalmic |
10 mg/1ml
|
| Solution | Intraocular |
230000 mg
|
| Injection | — |
10 mg/ml
|
| Injection, solution | Intravitreal |
100 mg/1mL
|
| Solution | Intravitreal |
100 mg / mL
|